BREAKING
Csx Jumps 6.6% After TD Cowen Maintains Buy 15 minutes ago Powell Industries Jumps 5.8% Amid Sector-Wide Rally 17 minutes ago UiPath Drops 8.3% Amid Sector-Wide Selling 19 minutes ago Charles River Laboratories International Drops 7.2% Amid Sector-Wide Selling 21 minutes ago DXC Technology Drops 7.0% Amid Sector-Wide Selling 23 minutes ago Q2 Holdings Drops 7.5% Amid Sector-Wide Selling 24 minutes ago Autodesk Drops 6.9% Amid Sector-Wide Selling 24 minutes ago Bentley Systems Drops 7.0% Amid Sector-Wide Selling 25 minutes ago BILL Holdings Drops 7.1% Amid Sector-Wide Selling 25 minutes ago SolarEdge Technologies Jumps 8.8% After Citigroup Maintains Sell 26 minutes ago Csx Jumps 6.6% After TD Cowen Maintains Buy 15 minutes ago Powell Industries Jumps 5.8% Amid Sector-Wide Rally 17 minutes ago UiPath Drops 8.3% Amid Sector-Wide Selling 19 minutes ago Charles River Laboratories International Drops 7.2% Amid Sector-Wide Selling 21 minutes ago DXC Technology Drops 7.0% Amid Sector-Wide Selling 23 minutes ago Q2 Holdings Drops 7.5% Amid Sector-Wide Selling 24 minutes ago Autodesk Drops 6.9% Amid Sector-Wide Selling 24 minutes ago Bentley Systems Drops 7.0% Amid Sector-Wide Selling 25 minutes ago BILL Holdings Drops 7.1% Amid Sector-Wide Selling 25 minutes ago SolarEdge Technologies Jumps 8.8% After Citigroup Maintains Sell 26 minutes ago
ADVERTISEMENT
Breaking News

Thermo Fisher Scientific Releases Q1 2026 Financial Results

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%).

April 23, 2026 1 min read

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%).

TMOTMO|EPS $5.44 vs $5.28 est (+3.0%)|Rev $11.01B|Net Income $1.65B

Thermo Fisher Scientific Inc. (TMO) reported Q1 2026 adjusted earnings of $5.44 per share, beating the $5.28 consensus estimate (beat by 3.0%). Revenue totaled $11.01B for the quarter. Revenue was up 6.0% year-over-year.

Thermo Fisher Scientific Inc. is a Diagnostics & Research company. Organic revenue growth was +1.0% for the quarter. Laboratory Products and Biopharma Services generated $6.04B in revenue for the quarter. The company earned $2.03B in adjusted net income.

Wall Street consensus stands at 20 buy, 4 hold, 0 sell.

A detailed analysis of Thermo Fisher Scientific Inc.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT